Skip to main content
HSPUF
OTC Real Estate & Construction

HSPO Signs $2B Business Combination with ArcheNova Biotech, Targets Nasdaq Listing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Real Estate
Sentiment info
Positive
Importance info
9
Price
$11.21
Mkt Cap
$23.616M
52W Low
$10.05
52W High
$29.7
52W Position info
12% above low
Off High info
62% below high
Rel. Volume
Market data snapshot near publication time

HSPUF is trading near its 52-week low of $10.05 (12% above the low).

Summary

HSPO signed a definitive business combination agreement with ArcheNova Biotech Corp. at a $2.0 billion valuation, targeting a Nasdaq listing with closing expected in Q1 2027.


Key Events · M&A and Partnerships · HSPUF

  • Definitive Business Combination Agreement Signed

    On October 12, 2026, HSPO entered into a business combination agreement with ArcheNova Biotech Corp., valuing ArcheNova at $2.0 billion (Company Equity Value).

  • Exchange Ratio and Consideration

    ArcheNova shareholders will receive PubCo Ordinary Shares at an exchange ratio of $2.0B divided by $10.00 per share, divided by ArcheNova's outstanding ordinary shares. HSPO shareholders receive one PubCo Ordinary Share per HSPO share.

  • Nasdaq Listing Planned

    PubCo Ordinary Shares are expected to be listed on Nasdaq following consummation, with closing targeted for Q1 2027 subject to regulatory and shareholder approvals.

  • Trust Account Balance

    As of October 5, 2026, HSPO's trust account held approximately $760,873.03, a modest cash position relative to the $2.0B valuation, implying reliance on target capital or additional financing.


Analysis · HSPUF · Real Estate & Construction

A definitive business combination agreement has been signed with ArcheNova Biotech Corp., a clinical-stage MSC-exosome biopharmaceutical company, at a $2.0 billion enterprise value. This marks the SPAC's long-awaited de-SPAC transaction after a prior business combination was terminated and a going concern warning was issued. The deal would take ArcheNova public on Nasdaq, with closing expected in Q1 2027. The trust account holds only about $760,873, meaning the combined company will rely heavily on the target's own capital and any PIPE financing. For HSPO shareholders, this is a thesis-altering event: the company transforms from a distressed blank-check vehicle into a Nasdaq-listed biotech, though execution risk remains high given the small trust balance, shareholder redemption risk, and the need for regulatory and shareholder approvals.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HSPUF was trading at $11.21 on OTC in the Real Estate & Construction sector, with a market capitalization of approximately $23.6M. The 52-week trading range was $10.05 to $29.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HSPUF - Latest Insights

HSPUF
May 14, 2026, 8:53 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $12.70
Real-time Price: $11.21 info
Change: -$1.49 (-12%) info
Market Cap: $23.616M info
HSPUF
Apr 23, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.70
Real-time Price: $11.21 info
Change: -$1.49 (-12%) info
Market Cap: $23.616M info